Ex-Al­ler­gan prez In­gram forges $1B deal to sell Alzheimer’s biotech to Brent Saun­ders and the new crew at Al­ler­gan

Just a year af­ter ex-Al­ler­gan pres­i­dent Doug In­gram took the helm of a low-pro­file biotech named Chase Phar­ma­ceu­ti­cals and helped steer an ex­per­i­men­tal ther­a­py for Alzheimer’s through a suc­cess­ful, though small, Phase II study, he’s arranged a sale of the com­pa­ny to Brent Saun­ders and the new team run­ning Al­ler­gan.

Al­ler­gan CEO Saun­ders agreed to hand over $125 mil­lion in a cash up­front to ac­quire Irvine, CA-based Chase, and a spokesper­son for the com­pa­ny says mile­stones bring the to­tal val­ue of the deal up to a po­ten­tial $1 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER